title: [Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma].
abstract: Bisphosphonates are indicated for the treatment of bone lesions in patients with solid tumours or multiple myeloma. Bisphosphonates have proven their effectiveness in reducing the number of bone complications (hypercalcemia, pain, disease-related fractures, spinal cord compression) and delaying their occurrence in patients with bone tumours; they have also been shown to reduce the need for bone surgery and palliative or pain-relieving radiotherapy in these patients. International recommendations for the treatment of bone lesions related to malignant solid tumours and multiple myeloma have been established. We have elaborated clinical practice guidelines on the use of bisphosphonates to assist treatment decision-making in bone oncology. The guide contains decision trees and tables with information to guide pre-treatment evaluation and patient follow-up, as well as indications and conditions of use of bisphosphonates. In 2007, the regional cancer network of Rhône-Alpes, ONCORA, formed a working group (GIP ONCORA) to elaborate the guideline. The final version was then discussed and adopted at a plenary session in July 2009, during a collaborative workshop on supportive care recommendations organized by ONCORA and the regional cancer network of Lorraine.
authors.affiliation: Service de rhumatologie, centre hospitalier de Villefranche/Saône, BP 436, 69655 Villefranche/Saône cedex, France. jfbrantus@ch-villefranche.fr
authors.forename: J F
authors.initials: JF
authors.lastname: Brantus
authors.forename: C
authors.initials: C
authors.lastname: Roemer-Becuwe
authors.forename: P
authors.initials: P
authors.lastname: Cony-Makhoul
authors.forename: S
authors.initials: S
authors.lastname: Salino
authors.forename: A
authors.initials: A
authors.lastname: Fontana
authors.forename: P
authors.initials: P
authors.lastname: Debourdeau
authors.forename: T
authors.initials: T
authors.lastname: Thomas
authors.forename: J P
authors.initials: JP
authors.lastname: Guastalla
authors.forename: H
authors.initials: H
authors.lastname: Ghesquieres
authors.forename: C
authors.initials: C
authors.lastname: Sebban
authors.forename: M
authors.initials: M
authors.lastname: Pavic
authors.forename: P
authors.initials: P
authors.lastname: Collet
authors.forename: J P
authors.initials: JP
authors.lastname: Larbre
authors.forename: S
authors.initials: S
authors.lastname: Martinon
authors.forename: F
authors.initials: F
authors.lastname: Brocard
authors.forename: A G
authors.initials: AG
authors.lastname: Bodard
authors.forename: G
authors.initials: G
authors.lastname: Blanc
authors.forename: V
authors.initials: V
authors.lastname: Balestrière
authors.forename: B
authors.initials: B
authors.lastname: Favier
authors.forename: F
authors.initials: F
authors.lastname: Farsi
authors.forename: I
authors.initials: I
authors.lastname: Krakowski
authors.forename: P
authors.initials: P
authors.lastname: Biron
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003663:Decision Trees; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates